BHWM
FLNA

Beaird Harris Wealth Management’s Filana Therapeutics FLNA Stock Holding History

Beaird Harris Wealth Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$4K – 701
2021
Q4 		$4K Buy
+100
New +$5.24K ﹤0.01% 504

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Beaird Harris Wealth Management's FLNA Position: Q1 2022 in Review

Beaird Harris Wealth Management sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 100 shares — an estimated $4K sold.

Beaird Harris Wealth Management first reported a position in FLNA in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

  • Beaird Harris Wealth Management reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 100 Filana Therapeutics shares in Q1 2022, an estimated $4K.
  • Beaird Harris Wealth Management first reported a position in Filana Therapeutics in Q4 2021 and held it in 1 quarter.
  • Beaird Harris Wealth Management's Filana Therapeutics position peaked at $4K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Beaird Harris Wealth Management's 13F filing for Q1 2022, filed 27 May 2022.